



19 June 2018

CardieX Completes First Investment in Wearable Partner Blumio, Inc

Highlights:

- **CardieX initiates first tranche of 7.5% investment into Blumio;**
- **First stage trial with Macquarie University fast tracked to leverage the combination of CardieX's IP and Blumio's wearable sensor;**
- **Cuffless, wearable blood pressure monitoring has been identified by CardieX as a multi-billion USD market opportunity;**
- **The combination of CardieX's IP together with Blumio's sensor has potential to significantly disrupt this market, including the diagnosis and treatment of hypertension and related cardiovascular disorders.**

CardieX Limited ("CDX") announced earlier this year it's proposed investment of up to USD \$600,000 to acquire up to 7.5% in Blumio (14 March 2018) by way of a Convertible Note (the "Note").

CDX is pleased to confirm that the first tranche of USD \$150,000 has now been paid, the second tranche of USD \$450,000 will be made on or before 30 November 2018, pursuant to the terms of the Note.

CardieX and Blumio are currently in first stage trials in partnership with Macquarie University to determine key diagnostic outputs from the Blumio sensor. The trial is being run and managed by CardieX under a Partnership and Collaboration Agreement between the companies.

Announcing the first investment, CardieX's CEO Craig Cooper commented: *"Cuffless, wearable blood pressure monitoring is a multi-billion dollar [\$USD] opportunity. The combination of CardieX's IP and trademarks together with Blumio's sensor has the potential to significantly disrupt the diagnosis and treatment of hypertension and related cardiovascular disorders".*

About CardieX

CardieX is a global health technology company focused on developing solutions for large-scale population health disorders. The Company's "AtCor Medical" division develops and markets products for the early detection of target organ damage and management of cardiovascular and renal disease.

About Blumio

Blumio Inc., is a Silicon Valley based California company that develops non-invasive radio frequency sensors designed to measure blood pressure and other cardiovascular diagnostics. CardieX recently announced an investment of up to US\$600,000 in Blumio to acquire up to 7.5% in the company (ASX 14 March 2018).

For more information please contact:

Chief Executive Officer
Craig Cooper
Ph: +61 429 993 399
ccooper@cardiex.com

Investor Relations
Peter Taylor
Ph: +61 412 036 231
peter@nwrcommunications.com.au

Chief Financial Officer
Jarrod White
Ph: +61 2 8296 0000
jwhite@cardiex.com